Search

Your search keyword '"Schinkel, Janke"' showing total 525 results
Start Over Author "Schinkel, Janke"
525 results on '"Schinkel, Janke"'

1. Design and Implementation of a Multilevel Intervention to Reduce Hepatitis C Transmission Among Men Who Have Sex With Men in Amsterdam: Co-Creation and Usability Study

Author

Prinsenberg, Tamara, Zantkuijl, Paul, Zuilhof, Wim, Davidovich, Udi, Schinkel, Janke, Prins, Maria, and van der Valk, Marc

Subjects
Medicine
Abstract

BackgroundIn the Netherlands, transmission of hepatitis C virus (HCV) occurs primarily among men who have sex with men (MSM). Early HCV testing of at-risk MSM and immediate initiation of treatment will prevent onward transmission, but this may not be sufficient to eliminate HCV in a population with ongoing risk behaviors. Therefore, targeted socioculturally acceptable preventive measures, including behavioral interventions, are urgently needed. Currently, little contextually appropriate information about HCV or risk reduction interventions is available. ObjectiveThe objective of this project was to develop an intervention to reduce HCV transmission among MSM in Amsterdam through a co-creation process, with the input of men from the targeted community directly impacting intervention content, design, and implementation. MethodsWe developed a multilevel intervention targeting 6 levels: individual, community, professional, context, patient, and network. The intervention was developed in close cooperation between health professionals, gay community members, commercial stakeholders, and stakeholders from within the gay community. The co-creation process had 4 phases: a needs assessment, stakeholder engagement, co-creation, and implementation. The co-creation phase continued until consensus was reached between the researchers and community members on the intervention content and design. The final intervention, NoMoreC, was completed within 2 years, and implementation started in February 2018. ResultsNoMoreC includes web-based and face-to-face components as well as an anonymous HCV testing service. The NoMoreC website provides information about hepatitis C, HCV transmission routes, risk reduction strategies, testing and treatment options, and partner notification. The face-to-face component comprises a risk reduction toolbox, training for health professionals, and providing tailored advice to sex on premises venues. NoMoreC is promoted by an active voluntary campaign team. ConclusionsInvolving the community and stakeholders in the creation of NoMoreC has been the main strength of this project. It has resulted in an intervention with various components that resonates with the gay community at risk of HCV infection. The uptake and acceptability of the described intervention will be evaluated in the future. The description of the co-creation process and implementation of the project may serve as a rich and useful source for others who want to develop culturally and context appropriate HCV interventions.

Published
2020
Full Text
View/download PDF

6. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies

Author

Hellard, Margaret E, Sacks-Davis, Rachel, van Santen, Daniela K, Stewart, Ashleigh, Ke, Tianhui, Zhang, Yanqin, Stoove, Mark, Guy, Rebecca, Pedrana, Alisa, Asselin, Jason, Dawe, Joshua, Wilkinson, Anna, Boyd, Anders, Smit, Colette, van der Valk, Marc, Schinkel, Janke, Wittkop, Linda, Salmon, Dominique, Sogni, Philippe, Esterle, Laure, Gilbert, Camille, Merchadou, Laurence, Gillet, Stephanie, Khan, Coralie, Bonnet, Fabrice, Leleux, Olivier, Le Marec, Fabien, Perrier, Adelaide, Matthews, Gail, Shaw, Ineke, Martinello, Marianne, Applegate, Tanya, Carson, Joanne, Doyle, Joseph S, Harney, Brendan, Bryant, Melissa, Jarrin Vera, Inmaculada, Berenguer, Juan, Alejos, Belen, Lazarus, Jeffrey V, Moreno, Cristina, Izquierdo, Rebecca, Rava, Marta, Klein, Marina, Wang, Shouao, Lumia, Jessica, Pexos, Costa, Peiris, Hansi, Saeed, Sahar, Moodie, Erica, Young, Jim, Pick, Neora, Conway, Brian, Hull, Mark, Wong, Alex, Gill, John, Barrett, Lisa, Cohen, Jeff, Cox, Joseph, Cote, Pierre, Haider, Shariq, Rouleau, Danielle, Vachon, Marie-Louise, Rachlis, Anita, Sandre, Roger, Walmsley, Sharon, Sadr, Aida, Cooper, Curtis, Sanche, Steve, Rauch, Andri, Mugglin, Catrina, Salazar-Viscaya, Luisa, Kusejko, Katharina, Prins, Maria, Hage, Kris, Lacombe, Karine, Requena, Maria-Bernada, Girard, Pierre-Marie, Brucker, Matthieu, Vincensini, Jean-Paul, Jarrin, Inmaculada, Requena, Maria-Bernarda, Matthews, Gail V, Martin, Natasha K, Spelman, Tim, and Hellard, Margaret

Published
2024
Full Text
View/download PDF

8. Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses

Author

Radić, Laura, Sliepen, Kwinten, Yin, Victor, Brinkkemper, Mitch, Capella-Pujol, Joan, Schriek, Angela I., Torres, Jonathan L., Bangaru, Sandhya, Burger, Judith A., Poniman, Meliawati, Bontjer, Ilja, Bouhuijs, Joey H., Gideonse, David, Eggink, Dirk, Ward, Andrew B., Heck, Albert J.R., Van Gils, Marit J., Sanders, Rogier W., and Schinkel, Janke

Published
2023
Full Text
View/download PDF

9. Hepatitis C virus transmission between eight high-income countries among men who have sex with men: a whole-genome analysis

Author

Adams, Tanya, Amjad, Sophia, Appelhans, Christina, Applegate, Tanya, Becker, Brigitta, Bhagani, Sanjay, Bouchard, Rachel, Braun, Dominique, Bruelisauer, Christine, Bruneau, Julie, Calcagnile, Selma, Carroll, Anne, Cerocchi, Orlando, Chronister, Karen, Cordes, Christiane, Dore, Greg, Evans, Fiona, Fedele, Serge, Feld, Jordan, Ferguson, Catherine, Fraser, Chris, Ganase, Bruce, Gane, Ed, George, Valerie, Gerlach, Christoph, Gilleece, Yvonne, Gilliver, Rosie, Grebely, Jason, Grube, Christina, Gustafson, Jenna, Haas, Annette, Hagenauer, Michelle, Harris, Marianne, Helder, Jeltje, Hellard, Margaret, Hirter, Daniela, Hull, Mark, Ingiliz, Patrick, Katz, Stephanie, Kim, Arthur, Kotsoros, Barbara, Lacalamita, Melanie, Lindergard, Gabriella, Lutz, Thomas, Macabodbod, Lester, Manz, Manuela, Marks, Pip, Martinello, Marianne, Matthews, Gail, Messina, Paola, Mohrmann, Karina, Monnich, Christine, Moon, Juhi, Moriggia, Alberto, Morris, Genevieve, Morrish, Thomas, Nelson, Mark, Oliver, Victoria, Patterson, Joanne, Peters, Martine, Petoumenos, Kathy, Porretta, Hadassa, Rauch, Andri, Raymode, Parizade, Read, Phillip, Reece, Stacey, Rockstroh, Jürgen, Saidi, Angelika, Sasadeusz, Joe, Scherler, Pia, Schröder, Reinhold, Selfridge, Marion, Sevehon, Alison, Shaw, David, Sulkowski, Mark, Tamaddoni, Mahshid, Thunder, Orla, Thurnheer, Maria Christine, Tu, Elise, Ustianowski, Andrew, van der Valk, Marc, Witele, Eric, Koopsen, Jelle, Rockstroh, Juergen, Applegate, Tanya L, Sacks-Davis, Rachel, Boesecke, Christoph, Rebers, Sjoerd, Dore, Gregory J, and Schinkel, Janke

Published
2023
Full Text
View/download PDF

10. Epidemiologic and Genomic Analysis of SARS-CoV-2 Delta Variant Superspreading Event in Nightclub, the Netherlands, June 2021

Author

Koopsen, Jelle, van Ewijk, Oatharina E., Bavalia, Roisin, Cornelissen, Akke, Bruisten, Sylvia M., de Gee, Floor, Han, Alvin X., de Jong, Maarten, de Jong, Menno D., Jonges, Marcel, Khawaja, Norin, Koene, Fleur M.H.P.A., van der Lubben, Mariken, Mikulic, Iris, Rebers, Sjoerd P.H., Russell, Colin A., Schinkel, Janke, Schrejer, Anja J.M., Uil, Judith A. den, Welkers, Matthijs R.A., and Leenstra, Tjalling

Subjects
Epidemics -- Risk factors -- Causes of -- Netherlands, Nightclubs -- Health aspects, Disease transmission -- Risk factors -- Causes of, Company distribution practices, Health
Abstract

Because of decreasing severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) incidence rates in the Netherlands at the time, the government of the Netherlands lifted most restrictions on June 26, [...]

Published
2022
Full Text
View/download PDF

11. Induction of cross-neutralizing antibodies by a permuted hepatitis C virus glycoprotein nanoparticle vaccine candidate

Author

Sliepen, Kwinten, Radić, Laura, Capella-Pujol, Joan, Watanabe, Yasunori, Zon, Ian, Chumbe, Ana, Lee, Wen-Hsin, de Gast, Marlon, Koopsen, Jelle, Koekkoek, Sylvie, del Moral-Sánchez, Iván, Brouwer, Philip J. M., Ravichandran, Rashmi, Ozorowski, Gabriel, King, Neil P., Ward, Andrew B., van Gils, Marit J., Crispin, Max, Schinkel, Janke, and Sanders, Rogier W.

Published
2022
Full Text
View/download PDF

12. Broadening sarbecovirus neutralization with bispecific antibodies combining distinct conserved targets on the receptor binding domain

Author

Guerra, Denise, primary, Radić, Laura, additional, Brinkkemper, Mitch, additional, Poniman, Meliawati, additional, van der Maas, Lara, additional, Torres, Jonathan L., additional, Ward, Andrew B., additional, Sliepen, Kwinten, additional, Schinkel, Janke, additional, Sanders, Rogier W., additional, van Gils, Marit J., additional, and Beaumont, Tim, additional

Published
2024
Full Text
View/download PDF

13. Head-to-head validation of six immunoassays for SARS-CoV-2 in hospitalized patients

Author

van Agtmael, M., Algera, A.G., van Baarle, F., Bax, D., Beudel, M., Bogaard, H.J., Bomers, M., Bos, L., Botta, M., de Brabander, J., Brouwer, M.C., de Bruin, S., Bugiani, M., Bulle, E., Chouchane, O., Cloherty, A., Elbers, P., Fleuren, L., Geerlings, S., Geerts, B., Geijtenbeek, T., Girbes, A., Goorhuis, A., Grobusch, M.P., Hafkamp, F., Hagens, L., Hamann, J., Harris, V., Hemke, R., Hermans, S.M., Heunks, L., Hollmann, M.W., Horn, J., Hovius, J.W., Koning, R., van Mourik, N., Nellen, J., Paulus, F., Peters, E., van der Poll, T., Preckel, B., Prins, J.M., Raasveld, J., Reijnders, T., Schinkel, M., Schultz, M.J., Schuurman, A., Sigaloff, K., Smit, M., Stijnis, C.S., Stilma, W., Thoral, P., Tsonas, A., van der Valk, M., Veelo, D., Vlaar, A.P.J., de Vries, H., Wiersinga, W.J., Wouters, D., Zwinderman, A.H., van de Beek, D., Zonneveld, Rens, Jurriaans, Suzanne, van Gool, Tom, Hofstra, Jorrit J., Hekker, Thecla A.M., Defoer, Pien, Broekhuizen-van Haaften, Patricia E., Wentink-Bonnema, Ellen M., Boonkamp, Lynn, Teunissen, Charlotte E., Heijboer, Annemieke C., Martens, Frans, de Bree, Godelieve, van Vugt, Michele, van Houdt, Robin, Schinkel, Janke, and de Jong, Menno D.

Published
2021
Full Text
View/download PDF

14. HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study

Author

van der Valk, M., Geerlings, S.E., Goorhuis, A., Hovius, J.W., Lempkes, B., Nellen, F.J.B., van der Poll, T., Prins, J.M., van Vugt, M., Wiersinga, W.J., Wit, F.W.M.N., van Duinen, M., van Eden, J., Hazenberg, A., van Hes, A.M.H., Pijnappel, F.J.J., Smalhout, S.Y., Weijsenfeld, A.M., Jurriaans, S., Back, N.K.T., Zaaijer, H.L., Berkhout, B., Cornelissen, M.T.E., Schinkel, C.J., Wolthers, K.C., Peters, E.J.G., van Agtmael, M.A., Autar, R.S., Bomers, M., Sigaloff, K.C.E., Heitmuller, M., Laan, L.M., Ang, C.W., van Houdt, R., Jonges, M., van den Berge, M., Stegeman, A., Baas, S., Hage de Looff, L., Buiting, A., Reuwer, A., Veenemans, J., Wintermans, B., Pronk, M.J.H., Ammerlaan, H.S.M., van den Bersselaar, D.N.J., de Munnik, E.S., Deiman, B., Jansz, A.R., Scharnhorst, V., Tjhie, J., Wegdam, M.C.A., van Eeden, A., Nellen, J., Brokking, W., Elsenburg, L.J.M., Nobel, H., van Kasteren, M.E.E., Berrevoets, M.A.H., Brouwer, A.E., Adams, A., van Erve, R., de Kruijf-van de Wiel, B.A.F.M., Keelan-Phaf, S., van de Ven, B., Buiting, A.G.M., Murck, J.L., de Vries-Sluijs, T.E.M.S., Bax, H.I., van Gorp, E.C.M., de Jong-Peltenburg, N.C., de Mendonça Melo, M., van Nood, E., Nouwen, J.L., Rijnders, B.J.A., Rokx, C., Schurink, C.A.M., Slobbe, L., Verbon, A., Bassant, N., van Beek, J.E.A., Vriesde, M., van Zonneveld, L.M., de Groot, J., Boucher, C.A.B., Koopmans, M.P.G., van Kampen, J.J.A., Branger, J., Douma, R.A., Cents-Bosma, A.S., Duijf-van de Ven, C.J.H.M., Schippers, E.F., van Nieuwkoop, C., van IJperen, J.M., Geilings, J., van Burgel, N.D., Leyten, E.M.S., van der Hut, G., Gelinck, L.B.S., Mollema, F., Davids-Veldhuis, S., Tearno, C., Wildenbeest, G.S., Heikens, E., Groeneveld, P.H.P., Bouwhuis, J.W., Lammers, A.J.J., Kraan, S., van Hulzen, A.G.W., Kruiper, M.S.M., van der Bliek, G.L., Bor, P.C.J., Debast, S.B., Wagenvoort, G.H.J., Kroon, F.P., de Boer, M.G.J., Jolink, H., Lambregts, M.M.C., Roukens, A.H.E., Scheper, H., Dorama, W., van Holten, N., Claas, E.C.J., Wessels, E., den Hollander, J.G., Brouwer, C.J., Smit, J.V., Struik-Kalkman, D., van Niekerk, T., El Moussaoui, R., Pogany, K., Pontesilli, O., Lowe, S.H., Oude Lashof, A.M.L., Posthouwer, D., van Wolfswinkel, M.E., Ackens, R.P., Burgers, K., Schippers, J., Weijenberg-Maes, B., van Loo, I.H.M., Havenith, T.R.A., van Vonderen, M.G.A., Kampschreur, L.M., Faber, S., Steeman-Bouma, R., Al Moujahid, A., Kootstra, G.J., Delsing, C.E., van der Burg-van de Plas, M., Scheiberlich, L., Kortmann, W., van Twillert, G., Renckens, R., Ruiter-Pronk, D., van Truijen-Oud, F.A., Cohen Stuart, J.W.T., Jansen, E.R., Hoogewerf, M., Rozemeijer, W., van der Reijden, W.A., Sinnige, J.C., Brinkman, K., van den Berk, G.E.L., Blok, W.L., Lettinga, K.D., de Regt, M., Schouten, W.E.M., Stalenhoef, J.E., Veenstra, J., Vrouenraets, S.M.E., Blaauw, H., Geerders, G.F., Kleene, M.J., Kok, M., Knapen, M., van der Meché, I.B., Mulder-Seeleman, E., Toonen, A.J.M., Wijnands, S., Wttewaal, E., Kwa, D., van Crevel, R., Dofferhoff, A.S.M., ter Hofstede, H.J.M., Hoogerwerf, J., Keuter, M., Richel, O., Albers, M., Grintjes-Huisman, K.J.T., de Haan, M., Marneef, M., Strik-Albers, R., Rahamat-Langendoen, J., Stelma, F.F., Burger, D., Gisolf, E.H., Hassing, R.J., Claassen, M., ter Beest, G., van Bentum, P.H.M., Langebeek, N., Tiemessen, R., Swanink, C.M.A., van Lelyveld, S.F.L., Soetekouw, R., van der Prijt, L.M.M., van der Swaluw, J., Bermon, N., Jansen, R., Herpers, B.L., Veenendaal, D., Verhagen, D.W.M., Lauw, F.N., van Broekhuizen, M.C., van Wijk, M., Bierman, W.F.W., Bakker, M., Kleinnijenhuis, J., Kloeze, E., Middel, A., Postma, D.F., Stienstra, Y., Wouthuyzen-Bakker, M., Boonstra, A., de Groot-de Jonge, H., van der Meulen, P.A., de Weerd, D.A., Niesters, H.G.M., van Leer-Buter, C.C., Knoester, M., Hoepelman, A.I.M., Arends, J.E., Barth, R.E., Bruns, A.H.W., Ellerbroek, P.M., Mudrikova, T., Oosterheert, J.J., Schadd, E.M., van Welzen, B.J., Aarsman, K., Griffioen-van Santen, B.M.G., de Kroon, I., van Berkel, M., van Rooijen, C.S.A.M., Schuurman, R., Verduyn-Lunel, F., Wensing, A.M.J., Reiss, P., Zaheri, S., Boyd, A.C., Bezemer, D.O., van Sighem, A.I., Smit, C., Hillebregt, M., de Jong, A., Woudstra, T., Bergsma, D., Meijering, R., van de Sande, L., Rutkens, T., van der Vliet, S., de Groot, L., van den Akker, M., Bakker, Y., El Berkaoui, A., Bezemer, M., Brétin, N., Djoechro, E., Groters, M., Kruijne, E., Lelivelt, K.J., Lodewijk, C., Lucas, E., Munjishvili, L., Paling, F., Peeck, B., Ree, C., Regtop, R., Ruijs, Y., Schoorl, M., Schnörr, P., Scheigrond, A., Tuijn, E., Veenenberg, L., Visser, K.M., Witte, E.C., Smit, Colette, Boyd, Anders, Rijnders, Bart J A, van de Laar, Thijs J W, Leyten, Eliane M, Bierman, Wouter F, Brinkman, Kees, Claassen, Mark A A, den Hollander, Jan, Boerekamps, Anne, Newsum, Astrid M, Schinkel, Janke, Prins, Maria, Arends, Joop E, Op de Coul, Eline L M, van der Valk, Marc, and Reiss, Peter

Published
2021
Full Text
View/download PDF

15. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies

Author

Sacks-Davis, Rachel, primary, van Santen, Daniela K, additional, Boyd, Anders, additional, Young, Jim, additional, Stewart, Ashleigh, additional, Doyle, Joseph S, additional, Rauch, Andri, additional, Mugglin, Catrina, additional, Klein, Marina, additional, van der Valk, Marc, additional, Smit, Colette, additional, Jarrin, Inmaculada, additional, Berenguer, Juan, additional, Lacombe, Karine, additional, Requena, Maria-Bernarda, additional, Wittkop, Linda, additional, Leleux, Olivier, additional, Bonnet, Fabrice, additional, Salmon, Dominique, additional, Matthews, Gail V, additional, Guy, Rebecca, additional, Martin, Natasha K, additional, Spelman, Tim, additional, Prins, Maria, additional, Stoove, Mark, additional, Hellard, Margaret, additional, Hellard, Margaret E, additional, Sacks-Davis, Rachel, additional, Ke, Tianhui, additional, Zhang, Yanqin, additional, Pedrana, Alisa, additional, Asselin, Jason, additional, Dawe, Joshua, additional, Wilkinson, Anna, additional, Schinkel, Janke, additional, Sogni, Philippe, additional, Esterle, Laure, additional, Gilbert, Camille, additional, Merchadou, Laurence, additional, Gillet, Stephanie, additional, Khan, Coralie, additional, Le Marec, Fabien, additional, Perrier, Adelaide, additional, Matthews, Gail, additional, Shaw, Ineke, additional, Martinello, Marianne, additional, Applegate, Tanya, additional, Carson, Joanne, additional, Harney, Brendan, additional, Bryant, Melissa, additional, Jarrin Vera, Inmaculada, additional, Alejos, Belen, additional, Lazarus, Jeffrey V, additional, Moreno, Cristina, additional, Izquierdo, Rebecca, additional, Rava, Marta, additional, Wang, Shouao, additional, Lumia, Jessica, additional, Pexos, Costa, additional, Peiris, Hansi, additional, Saeed, Sahar, additional, Moodie, Erica, additional, Pick, Neora, additional, Conway, Brian, additional, Hull, Mark, additional, Wong, Alex, additional, Gill, John, additional, Barrett, Lisa, additional, Cohen, Jeff, additional, Cox, Joseph, additional, Cote, Pierre, additional, Haider, Shariq, additional, Rouleau, Danielle, additional, Vachon, Marie-Louise, additional, Rachlis, Anita, additional, Sandre, Roger, additional, Walmsley, Sharon, additional, Sadr, Aida, additional, Cooper, Curtis, additional, Sanche, Steve, additional, Salazar-Viscaya, Luisa, additional, Kusejko, Katharina, additional, Hage, Kris, additional, Requena, Maria-Bernada, additional, Girard, Pierre-Marie, additional, Brucker, Matthieu, additional, and Vincensini, Jean-Paul, additional

Published
2024
Full Text
View/download PDF

19. Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial

Author

Boerekamps, Anne, De Weggheleire, Anja, van den Berk, Guido E, Lauw, Fanny N, Claassen, Mark A A, Posthouwer, Dirk, Bierman, Wouter F, Hullegie, Sebastiaan J, Popping, Stephanie, van de Vijver, David A C M, Dofferhoff, Anthonius S M, Kootstra, Gert Jan, Leyten, Eliane M, den Hollander, Jan, van Kasteren, Marjo E, Soetekouw, Robert, Ammerlaan, Heidi S M, Schinkel, Janke, Florence, Eric, Arends, Joop E, and Rijnders, Bart J A

Published
2019
Full Text
View/download PDF

20. Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study

Author

Hajarizadeh, Behzad, Grady, Bart, Page, Kimberly, Kim, Arthur Y, McGovern, Barbara H, Cox, Andrea L, Rice, Thomas M, Sacks-Davis, Rachel, Bruneau, Julie, Morris, Meghan, Amin, Janaki, Schinkel, Janke, Applegate, Tanya, Maher, Lisa, Hellard, Margaret, Lloyd, Andrew R, Prins, Maria, Geskus, Ronald B, Dore, Gregory J, Grebely, Jason, and Group, InC3Study

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, HIV/AIDS, Digestive Diseases, Hepatitis - C, Liver Disease, Chronic Liver Disease and Cirrhosis, Emerging Infectious Diseases, Infectious Diseases, Hepatitis, Clinical Research, Genetics, Infection, Good Health and Well Being, Adult, Cohort Studies, Female, Genotype, Hepacivirus, Hepatitis C, Humans, Interferons, Interleukins, Male, RNA, Viral, Substance Abuse, Intravenous, Viral Load, Young Adult, Viral load, Acute HCV, IFNL3 genotype, IL28B genotype, Cohort study, InC(3)Study Group, Microbiology, Clinical Sciences, Virology, Clinical sciences, Medical microbiology
Abstract

Background and objectivesHepatitis C virus (HCV) RNA level in acute HCV infection is predictive of spontaneous clearance. This study assessed factors associated with HCV RNA levels during early acute infection among people who inject drugs with well-defined acute HCV infection.Study designData were from International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC(3)) Study, an international collaboration of nine prospective cohorts studying acute HCV infection. Individuals with available HCV RNA levels during early acute infection (first two months following infection) were included. The distribution of HCV RNA levels during early acute infection were compared by selected host and virological factors.ResultsA total of 195 individuals were included. Median HCV RNA levels were significantly higher among individuals with interferon lambda 3 (IFNL3, formerly called IL28B) CC genotype compared to those with TT/CT genotype (6.28 vs. 5.39logIU/mL, respectively; P=0.01). IFNL3 CC genotype was also associated with top tertile HCV RNA levels (≥6.3log IU/mL; vs. TT/CT genotype; adjusted Odds Ratio: 4.28; 95%CI: 2.01, 9.10; P

Published
2014

21. Joint statement in support of hepatitis C human challenge studies

Author

Alter, Harvey J, primary, Barnes, Eleanor, additional, Biondi, Mia J, additional, Cox, Andrea L, additional, Eberts, Jake D, additional, Feld, Jordan J, additional, Liang, T Jake, additional, Morrison, Josh, additional, Rice, Charles M, additional, Shoukry, Naglaa H, additional, Thomas, David L, additional, Van Gennip, Jennifer, additional, Weijer, Charles, additional, Aghemo, Alessio, additional, Akiyama, Matthew, additional, Ali, Mohammad, additional, Alter, Harvey, additional, Bader, Ralf, additional, Bailey, Justin R., additional, Balaban, Yasemin, additional, Banerjee, Sayantan, additional, Bartenschlager, Ralf, additional, Baumert, Thomas F., additional, Berenguer, Marina, additional, Bhadoria, Ajeet S., additional, Biondi, Mia, additional, Bonanni, Paolo, additional, Bonella, Alcino E., additional, Bruggmann, Philip, additional, Bruneau, Julie, additional, Bull, Rowena A., additional, Butsashvili, Maia, additional, Cahn, Pedro, additional, Caplan, Arthur L., additional, Chappell, Richard Y., additional, Chisari, Francis, additional, Chung, Ray, additional, Cooke, Graham, additional, Cox, Andrea L., additional, Dalgard, Olav, additional, Dao, Doan Y., additional, Darzi, Ara, additional, Dieterich, Douglas, additional, Dillon, John F., additional, Dore, Gregory J., additional, Doyle, Joseph S., additional, Drummer, Heidi E., additional, Durbin, Anna P., additional, Dusheiko, Geoffrey, additional, Eberts, Jake D., additional, Eyal, Nir, additional, Feld, Jordan, additional, Ferguson, Kyle, additional, Flisiak, Robert, additional, Forns, Xavier, additional, Foster, Graham R., additional, Foung, Steven, additional, Gal-Tanamy, Meital, additional, Gane, Ed, additional, Gehring, Adam J., additional, George, Jacob, additional, Ghany, Marc G., additional, Gilbert, Daniel T., additional, Glaze, Kimberly, additional, Goodman, Kenneth W., additional, Grebely, Jason, additional, Hamid, Saeed, additional, Haybron, Daniel M., additional, Holton, Richard, additional, Ignarro, Louis J., additional, Jackson, Tamika, additional, Jamieson, Dale, additional, Jollimore, Jody, additional, Karaba, Andrew, additional, Klein, Marina, additional, Lauer, Georg, additional, Law, Mansun, additional, Lemon, Stanley M., additional, Liang, T. Jake, additional, Liu, Lin, additional, Lohmann, Volker, additional, Mak, Lung-Yi, additional, Marinho, Rui T., additional, Marsh, Abigail A., additional, Miller, Lesley, additional, Morrison, Joshua, additional, Negro, Francesco, additional, Nguyen, Bao-Vuong, additional, Page, Kimberly, additional, Paterson, Kerry, additional, Pedrana, Alisa, additional, Pietschmann, Thomas, additional, Pinker, Steven, additional, Plotkin, Stanley, additional, Ray, Stuart C., additional, Reau, Nancy, additional, Remak, William M., additional, Rice, Charles M., additional, Ridruejo, Ezequiel, additional, Roberts, Richard J., additional, Roth, Alvin, additional, Rouphael, Nadine, additional, Sanders, Rogier, additional, Sandvold, Russell, additional, Schafer, Arthur, additional, Schinkel, Janke, additional, Seto, Wai-Kay, additional, Shoukry, Naglaa, additional, Singer, Peter, additional, Solomon, Sunil, additional, Somerville, Chris, additional, Sonderup, Mark W., additional, Sulkowski, Mark, additional, Talaat, Kawsar, additional, Temkin, Larry, additional, Terrault, Norah, additional, Thio, Chloe, additional, Thomas, David L., additional, Thompson, Alexander J., additional, Tzarum, Netanel, additional, van der Valk, Marc, additional, Waked, Imam, additional, Walen, Alec, additional, Walker, Christopher M., additional, Wedemeyer, Heiner, additional, Wikler, Dan, additional, Wilkinson, Dominic, additional, Youngs, Heather, additional, Yuen, Man-fung, additional, Zack, Barry, additional, and Zinger, Ekaterina, additional

Published
2023
Full Text
View/download PDF

22. Screening for Hepatitis C Virus Reinfection Using a Behaviour-Based Risk Score among Men Who Have Sex with Men with HIV: Results from a Case–Control Diagnostic Validation Study

Author

Hage, Kris, primary, van de Kerkhof, Marita, additional, Boyd, Anders, additional, Carson, Joanne M., additional, Newsum, Astrid M., additional, Matser, Amy, additional, van der Valk, Marc, additional, Brinkman, Kees, additional, Arends, Joop E., additional, Lauw, Fanny N., additional, Rijnders, Bart J. A., additional, van Eeden, Arne, additional, Martinello, Marianne, additional, Matthews, Gail V., additional, Schinkel, Janke, additional, and Prins, Maria, additional

Published
2023
Full Text
View/download PDF

23. DC-SIGN Polymorphisms Associate with Risk of Hepatitis C Virus Infection Among Men who Have Sex with Men but not Among Injecting Drug Users

Author

MSM Observational Study of Acute Infection with Hepatitis C (MOSAIC) Study Group and Amsterdam Cohort Studies (ACS), Steba, Gaby S., Koekkoek, Sylvie M., Vanhommerig, Joost W., Brinkman, Kees, Kwa, David, Van Der Meer, Jan T. M., Prins, Maria, Berkhout, Ben, Tanck, Michael, Paxton, William A., Molenkamp, Richard, and Schinkel, Janke

Published
2018

24. HIV-1 exposure and immune activation enhance sexual transmission of Hepatitis C virus by primary Langerhans cells

Author

Nijmeijer, Bernadien M., Sarrami-Forooshani, Ramin, Steba, Gaby S., Schreurs, Renee RCE., Koekkoek, Sylvie M., Molenkamp, Richard, Schinkel, Janke, Reiss, Peter, van Heukelom, Matthijs L. Siegenbeek, van der Valk, Marc, Ribeiro, Carla MS., and Geijtenbeek, Teunis BH.

Subjects
Langerhans cells -- Health aspects, HIV infections -- Development and progression, Disease transmission -- Development and progression -- Research -- Analysis -- Health aspects -- Risk factors, MSM (Men who have sex with men) -- Health aspects, Hepatitis C -- Risk factors, Immune response -- Health aspects, Health
Abstract

Introduction: The significant rise in incidence of Hepatitis C virus (HCV) infection among men-who-have-sex-with-men (MSM) living with HIV-1 suggests that HCV under specific circumstances is transmitted via sexual contact. During sexual transmission HCV has to cross the epithelial barrier to either directly enter the blood stream or indirectly via mucosal immune cells. However, the mechanisms of sexual transmission of HCV remain unclear. We investigated the role of Langerhans cells (LCs) in HCV susceptibility during sexual contact as LCs are among the first cells in mucosal tissues to encounter invading viruses. Methods: We investigated the phenotype of primary LCs in anal biopsies from MSM living with HIV-1. To investigate the role of primary LCs in HCV infection and transmission, we have used both isolated primary skin LCs and the ex vivo tissue transmission model. Results: Our data identified an important role for mucosal LCs in facilitating HCV transmission after HIV-1 exposure or immune activation. LCs were detected within mucosal anal tissues obtained from HIV-1 positive MSM biopsies. In order to perform functional studies, we used primary LCs from skin, which have a similar phenotype as mucosal LCs. Immature LCs were neither infected nor transmitted HCV to hepatocytes. Notably, exposure to HIV-1 significantly increased HCV transmission by LCs in the ex vivo transmission model. HIV-1 replication was crucial for the increased HCV transmission as HIV-1 inhibitors significantly reduced HIV-1-induced HCV transmission. Moreover, tissue immune activation of LCs also increased HCV transmission to target cells. Conclusions: Thus, our data strongly indicate that HIV-1 or immune activation in MSM leads to capture of HCV by mucosal LCs, which might facilitate transmission to other cells or allow entry of HCV into the blood. This novel transmission mechanism by LCs also implicates that the activation state of LCs is an important cellular determinant for HCV susceptibility after sexual contact. Keywords: HIV-1; Langerhans Cells; Hepatitis C virus; Immune activation; Viral transmission; Men-who-have-Sex-with-Men, 1 | INTRODUCTION Globally, 115 million people are infected with Hepatitis C virus (HCV) whereas 37 million people are infected with HIV-1, and approximately two million infected with both HIV-1 [...]

Published
2019
Full Text
View/download PDF

25. Hepatitis C virus transmission between eight high-income countries among men who have sex with men: a whole-genome analysis

Author

Koopsen, Jelle, primary, Matthews, Gail, additional, Rockstroh, Juergen, additional, Applegate, Tanya L, additional, Bhagani, Sanjay, additional, Rauch, Andri, additional, Grebely, Jason, additional, Sacks-Davis, Rachel, additional, Ingiliz, Patrick, additional, Boesecke, Christoph, additional, Rebers, Sjoerd, additional, Feld, Jordan, additional, Bruneau, Julie, additional, Martinello, Marianne, additional, Hellard, Margaret, additional, Dore, Gregory J, additional, Schinkel, Janke, additional, van der Valk, Marc, additional, Adams, Tanya, additional, Amjad, Sophia, additional, Appelhans, Christina, additional, Applegate, Tanya, additional, Becker, Brigitta, additional, Bouchard, Rachel, additional, Braun, Dominique, additional, Bruelisauer, Christine, additional, Calcagnile, Selma, additional, Carroll, Anne, additional, Cerocchi, Orlando, additional, Chronister, Karen, additional, Cordes, Christiane, additional, Dore, Greg, additional, Evans, Fiona, additional, Fedele, Serge, additional, Ferguson, Catherine, additional, Fraser, Chris, additional, Ganase, Bruce, additional, Gane, Ed, additional, George, Valerie, additional, Gerlach, Christoph, additional, Gilleece, Yvonne, additional, Gilliver, Rosie, additional, Grube, Christina, additional, Gustafson, Jenna, additional, Haas, Annette, additional, Hagenauer, Michelle, additional, Harris, Marianne, additional, Helder, Jeltje, additional, Hirter, Daniela, additional, Hull, Mark, additional, Katz, Stephanie, additional, Kim, Arthur, additional, Kotsoros, Barbara, additional, Lacalamita, Melanie, additional, Lindergard, Gabriella, additional, Lutz, Thomas, additional, Macabodbod, Lester, additional, Manz, Manuela, additional, Marks, Pip, additional, Messina, Paola, additional, Mohrmann, Karina, additional, Monnich, Christine, additional, Moon, Juhi, additional, Moriggia, Alberto, additional, Morris, Genevieve, additional, Morrish, Thomas, additional, Nelson, Mark, additional, Oliver, Victoria, additional, Patterson, Joanne, additional, Peters, Martine, additional, Petoumenos, Kathy, additional, Porretta, Hadassa, additional, Raymode, Parizade, additional, Read, Phillip, additional, Reece, Stacey, additional, Rockstroh, Jürgen, additional, Saidi, Angelika, additional, Sasadeusz, Joe, additional, Scherler, Pia, additional, Schröder, Reinhold, additional, Selfridge, Marion, additional, Sevehon, Alison, additional, Shaw, David, additional, Sulkowski, Mark, additional, Tamaddoni, Mahshid, additional, Thunder, Orla, additional, Thurnheer, Maria Christine, additional, Tu, Elise, additional, Ustianowski, Andrew, additional, and Witele, Eric, additional

Published
2023
Full Text
View/download PDF

28. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial

Author

van der Ree, Meike H, de Vree, J Marleen, Stelma, Femke, Willemse, Sophie, van der Valk, Marc, Rietdijk, Svend, Molenkamp, Richard, Schinkel, Janke, van Nuenen, Ad C, Beuers, Ulrich, Hadi, Salah, Harbers, Marten, van der Veer, Eva, Liu, Kai, Grundy, John, Patick, Amy K, Pavlicek, Adam, Blem, Jacqueline, Huang, Michael, Grint, Paul, Neben, Steven, Gibson, Neil W, Kootstra, Neeltje A, and Reesink, Hendrik W

Published
2017
Full Text
View/download PDF

29. Hepatitis E in Long-Term Travelers from the Netherlands to Subtropical and Tropical Countries, 2008-2011

Author

Elfrink, Floortje, Overbosch, Femke W., Schinkel, Janke, Koen, Gerrit, and Sonder, Gerard J.B.

Subjects
Enzyme-linked immunosorbent assay -- Health aspects, Hepatitis E -- Diagnosis -- Health aspects, Travelers -- Health aspects, Disease susceptibility -- Diagnosis -- Health aspects, Medical research -- Health aspects, Infection -- Diagnosis -- Health aspects, Immunoglobulin G -- Health aspects, Developing countries -- Health aspects, Blood donation -- Health aspects, Health
Abstract

Hepatitis E virus (HEV) is a common cause of acute viral hepatitis worldwide (1). There are 4 genotypes of HEV. Genotypes 1 and 2 infect humans in developing countries in [...]

Published
2018
Full Text
View/download PDF

30. Optimal dosing and timing of high-dose corticosteroid therapy in hospitalized COVID-19 patients: study protocol for a retrospective observational multicenter study (SELECT) (Preprint)

Author

Daenen, Katrijn, primary, Huijben, Jilske, additional, Boyd, Anders, additional, Bos, Lieuwe, additional, Stoof, Sara, additional, van Willigen, Hugo, additional, Gommers, Diederik, additional, Moeniralam, Hazra, additional, den Uil, Corstiaan, additional, Juffermans, Nicole, additional, Kant, Merijn, additional, Valkenburg, Bram, additional, Pillay, Janesh, additional, van Meenen, David, additional, Paulus, Frederique, additional, Schultz, Marcus, additional, Dalm, Virgil, additional, van Gorp, Eric, additional, Schinkel, Janke, additional, and Endeman, Henrik, additional

Published
2023
Full Text
View/download PDF

31. Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study

Author

Isfordink, Cas J, primary, Boyd, Anders, additional, Sacks-Davis, Rachel, additional, van Santen, Daniela K, additional, Smit, Colette, additional, Martinello, Marianne, additional, Stoove, Mark, additional, Berenguer, Juan, additional, Wittkop, Linda, additional, Klein, Marina B, additional, Rauch, Andri, additional, Salmon, Dominique, additional, Lacombe, Karine, additional, Stewart, Ashleigh, additional, Schinkel, Janke, additional, Doyle, Joseph S, additional, Hellard, Margaret, additional, van der Valk, Marc, additional, and Matthews, Gail V, additional

Published
2023
Full Text
View/download PDF

32. Intent to vaccinate against SARS-CoV-2 and its determinants across six ethnic groups living in Amsterdam, the Netherlands: A cross-sectional analysis of the HELIUS study

Author

Campman, Sophie L., primary, van Rossem, Gwen, additional, Boyd, Anders, additional, Coyer, Liza, additional, Schinkel, Janke, additional, Agyemang, Charles, additional, Galenkamp, Henrike, additional, Koopman, Anitra D.M., additional, Leenstra, Tjalling, additional, Schim van der Loeff, Maarten, additional, Moll van Charante, Eric P., additional, van den Born, Bert-Jan H., additional, Lok, Anja, additional, Verhoeff, Arnoud, additional, Zwinderman, Aeilko H., additional, Jurriaans, Suzanne, additional, Stronks, Karien, additional, and Prins, Maria, additional

Published
2023
Full Text
View/download PDF

33. Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses

Author

Sub Biomol.Mass Spectrometry & Proteom., Afd Biomol.Mass Spect. and Proteomics, Biomolecular Mass Spectrometry and Proteomics, Radić, Laura, Sliepen, Kwinten, Yin, Victor, Brinkkemper, Mitch, Capella-Pujol, Joan, Schriek, Angela I, Torres, Jonathan L, Bangaru, Sandhya, Burger, Judith A, Poniman, Meliawati, Bontjer, Ilja, Bouhuijs, Joey H, Gideonse, David, Eggink, Dirk, Ward, Andrew B, Heck, Albert J R, Van Gils, Marit J, Sanders, Rogier W, Schinkel, Janke, Sub Biomol.Mass Spectrometry & Proteom., Afd Biomol.Mass Spect. and Proteomics, Biomolecular Mass Spectrometry and Proteomics, Radić, Laura, Sliepen, Kwinten, Yin, Victor, Brinkkemper, Mitch, Capella-Pujol, Joan, Schriek, Angela I, Torres, Jonathan L, Bangaru, Sandhya, Burger, Judith A, Poniman, Meliawati, Bontjer, Ilja, Bouhuijs, Joey H, Gideonse, David, Eggink, Dirk, Ward, Andrew B, Heck, Albert J R, Van Gils, Marit J, Sanders, Rogier W, and Schinkel, Janke

Published
2023

34. Screening for Hepatitis C Virus Reinfection Using a Behaviour-Based Risk Score among Men Who Have Sex with Men with HIV:Results from a Case–Control Diagnostic Validation Study

Author

Hage, Kris, van de Kerkhof, Marita, Boyd, Anders, Carson, Joanne M., Newsum, Astrid M., Matser, Amy, van der Valk, Marc, Brinkman, Kees, Arends, Joop E., Lauw, Fanny N., Rijnders, Bart J.A., van Eeden, Arne, Martinello, Marianne, Matthews, Gail V., Schinkel, Janke, Prins, Maria, Hage, Kris, van de Kerkhof, Marita, Boyd, Anders, Carson, Joanne M., Newsum, Astrid M., Matser, Amy, van der Valk, Marc, Brinkman, Kees, Arends, Joop E., Lauw, Fanny N., Rijnders, Bart J.A., van Eeden, Arne, Martinello, Marianne, Matthews, Gail V., Schinkel, Janke, and Prins, Maria

Abstract

We assessed the predictive capacity of the HCV-MOSAIC risk score, originally developed for primary early HCV infection, as a screening tool for HCV reinfection in 103 men who have sex with men (MSM) with HIV using data from the MOSAIC cohort, including MSM with HIV/HCV-coinfection who became reinfected (cases, n = 27) or not (controls, n = 76) during follow-up. The overall predictive capacity of the score was assessed using the area under the receiver operating characteristic (AUROC) curve. The effects of covariates on the receiver operating characteristic (ROC) curve were assessed using parametric ROC regression. The score cut-off validated for primary early infection (≥2.0) was used, from which the sensitivity and specificity were calculated. The AUROC was 0.74 (95% confidence interval (CI) = 0.63–0.84). Group sex significantly increased the predictive capacity. Using the validated cut-off, sensitivity was 70.4% (95%CI = 49.8–86.2%) and specificity was 59.2% (95%CI: 47.3–70.4%). External validation from a cohort of 25 cases and 111 controls, all MSM with HIV, resulted in a sensitivity of 44.0% (95%CI = 24.4–65.1) and specificity of 71.2% (95%CI = 61.8–79.4). The HCV-MOSAIC risk score may be useful for identifying individuals at risk of HCV reinfection. In sexual health or HIV-care settings, this score could help guide HCV-RNA testing in MSM with a prior HCV infection.

Published
2023

35. Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variants compared with Alpha variant in vaccinated individuals

Author

Andeweg, Stijn P., Vennema, Harry, Veldhuijzen, Irene, Smorenburg, Naomi, Schmitz, Dennis, Zwagemaker, Florian, Van Gageldonk-Lafeber, Arianne B., Hahne, Susan J.M., Reusken, Chantal, Knol, Mirjam J., Eggink, Dirk, Schinkel, Janke, Welkers, Matthijs R.A., Jonges, Marcel, Koopsen, Jelle, Jong, Menno D.de, Molenkamp, Richard, Nieuwenhuijse, David F., Sikkema, Reina S., Munnink, Bas B.Oude, Koopmans, Marion, van der Zanden, Adri, Manrho, Laura, Beer, Jessica de, Boers, Stefan A., Meijers, Erin, Vreeswijk, Tom, Sidorov, Igor A., Dunk, Djoo, Smit, Pieter W., Pas, Suzan D., Verweij, Jaco J., Stohr, Joep J.J.M., Dingemans, Jozef, Veer, Brian van der, Alphen, Lieke van, Savelkoul, Paul, Niesters, Hubert G.M., Forero, Erley F.Lizarazo, Fliss, Monika A., Gard, Lilli, Tanja, Anniek A.N., Schuurman10, Rob, Wensing, Annemarie M.J., Hofstra, L. Marije, Wertheim, Heiman F.L., Faber, Timor, Kroneman, Annelies, Mulder, Maarten, Schipper, Maarten, Andeweg, Stijn P., Vennema, Harry, Veldhuijzen, Irene, Smorenburg, Naomi, Schmitz, Dennis, Zwagemaker, Florian, Van Gageldonk-Lafeber, Arianne B., Hahne, Susan J.M., Reusken, Chantal, Knol, Mirjam J., Eggink, Dirk, Schinkel, Janke, Welkers, Matthijs R.A., Jonges, Marcel, Koopsen, Jelle, Jong, Menno D.de, Molenkamp, Richard, Nieuwenhuijse, David F., Sikkema, Reina S., Munnink, Bas B.Oude, Koopmans, Marion, van der Zanden, Adri, Manrho, Laura, Beer, Jessica de, Boers, Stefan A., Meijers, Erin, Vreeswijk, Tom, Sidorov, Igor A., Dunk, Djoo, Smit, Pieter W., Pas, Suzan D., Verweij, Jaco J., Stohr, Joep J.J.M., Dingemans, Jozef, Veer, Brian van der, Alphen, Lieke van, Savelkoul, Paul, Niesters, Hubert G.M., Forero, Erley F.Lizarazo, Fliss, Monika A., Gard, Lilli, Tanja, Anniek A.N., Schuurman10, Rob, Wensing, Annemarie M.J., Hofstra, L. Marije, Wertheim, Heiman F.L., Faber, Timor, Kroneman, Annelies, Mulder, Maarten, and Schipper, Maarten

Abstract

The extent to which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) break through infection- or vaccine-induced immunity is not well understood. We analyzed 28,578 sequenced SARS-CoV-2 samples from individuals with known immune status obtained through national community testing in the Netherlands from March to August 2021. We found evidence of an increased risk of infection by the Beta (B.1.351), Gamma (P.1), or Delta (B.1.617.2) variants compared with the Alpha (B.1.1.7) variant after vaccination. No clear differences were found between vaccines. However, the effect was larger in the first 14 to 59 days after complete vaccination compared with ≥60 days. In contrast to vaccine-induced immunity, there was no increased risk for reinfection with Beta, Gamma, or Delta variants relative to the Alpha variant in individuals with infection-induced immunity.

Published
2023

36. Optimal Dosing and Timing of High-Dose Corticosteroid Therapy in Hospitalized Patients With COVID-19:Study Protocol for a Retrospective Observational Multicenter Study (SELECT)

Author

Daenen, Katrijn, Huijben, Jilske A., Boyd, Anders, Bos, Lieuwe D.J., Stoof, Sara C.M., van Willigen, Hugo, Gommers, Diederik A.M.P.J., Moeniralam, Hazra S., den Uil, Corstiaan A., Juffermans, Nicole P., Kant, Merijn, Valkenburg, Abraham J., Pillay, Janesh, van Meenen, David M.P., Paulus, Frederique, Schultz, Marcus J., Dalm, Virgil A.S.H., van Gorp, Eric C.M., Schinkel, Janke, Endeman, Henrik, Daenen, Katrijn, Huijben, Jilske A., Boyd, Anders, Bos, Lieuwe D.J., Stoof, Sara C.M., van Willigen, Hugo, Gommers, Diederik A.M.P.J., Moeniralam, Hazra S., den Uil, Corstiaan A., Juffermans, Nicole P., Kant, Merijn, Valkenburg, Abraham J., Pillay, Janesh, van Meenen, David M.P., Paulus, Frederique, Schultz, Marcus J., Dalm, Virgil A.S.H., van Gorp, Eric C.M., Schinkel, Janke, and Endeman, Henrik

Abstract

Background: In hospitalized patients with COVID-19, the dosing and timing of corticosteroids vary widely. Low-dose dexamethasone therapy reduces mortality in patients requiring respiratory support, but it remains unclear how to treat patients when this therapy fails. In critically ill patients, high-dose corticosteroids are often administered as salvage late in the disease course, whereas earlier administration may be more beneficial in preventing disease progression. Previous research has revealed that increased levels of various biomarkers are associated with mortality, and whole blood transcriptome sequencing has the ability to identify host factors predisposing to critical illness in patients with COVID-19. Objective: Our goal is to determine the most optimal dosing and timing of corticosteroid therapy and to provide a basis for personalized corticosteroid treatment regimens to reduce morbidity and mortality in hospitalized patients with COVID-19. Methods: This is a retrospective, observational, multicenter study that includes adult patients who were hospitalized due to COVID-19 in the Netherlands. We will use the differences in therapeutic strategies between hospitals (per protocol high-dose corticosteroids or not) over time to determine whether high-dose corticosteroids have an effect on the following outcome measures: mechanical ventilation or high-flow nasal cannula therapy, in-hospital mortality, and 28-day survival. We will also explore biomarker profiles in serum and bronchoalveolar lavage fluid and use whole blood transcriptome analysis to determine factors that influence the relationship between high-dose corticosteroids and outcome. Existing databases that contain routinely collected electronic data during ward and intensive care admissions, as well as existing biobanks, will be used. We will apply longitudinal modeling appropriate for each data structure to answer the research questions at hand. Results: As of April 2023, data have been collected f

Published
2023

38. Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia

Author

Rodrigo, Chaturaka, Eltahla, Auda A., Bull, Rowena A., Grebely, Jason, Dore, Gregory J., Applegate, Tanya, Page, Kimberly, Bruneau, Julie, Morris, Meghan D., Cox, Andrea L., Osburn, William, Kim, Arthur Y., Schinkel, Janke, Shoukry, Naglaa H., Lauer, Georg M., Maher, Lisa, Hellard, Margaret, Prins, Maria, Estes, Chris, Razavi, Homie, Lloyd, Andrew R., and Luciani, Fabio

Published
2016

39. Joint statement in support of hepatitis C human challenge studies

Author

Aghemo, Alessio, Akiyama, Matthew, Ali, Mohammad, Alter, Harvey, Bader, Ralf, Bailey, Justin R., Balaban, Yasemin, Banerjee, Sayantan, Barnes, Eleanor, Bartenschlager, Ralf, Baumert, Thomas F., Berenguer, Marina, Bhadoria, Ajeet S., Biondi, Mia, Bonanni, Paolo, Bonella, Alcino E., Bruggmann, Philip, Bruneau, Julie, Bull, Rowena A., Butsashvili, Maia, Cahn, Pedro, Caplan, Arthur L., Chappell, Richard Y., Chisari, Francis, Chung, Ray, Cooke, Graham, Cox, Andrea L., Dalgard, Olav, Dao, Doan Y., Darzi, Ara, Dieterich, Douglas, Dillon, John F., Dore, Gregory J., Doyle, Joseph S., Drummer, Heidi E., Durbin, Anna P., Dusheiko, Geoffrey, Eberts, Jake D., Eyal, Nir, Feld, Jordan, Ferguson, Kyle, Flisiak, Robert, Forns, Xavier, Foster, Graham R., Foung, Steven, Gal-Tanamy, Meital, Gane, Ed, Gehring, Adam J., George, Jacob, Ghany, Marc G., Gilbert, Daniel T., Glaze, Kimberly, Goodman, Kenneth W., Grebely, Jason, Hamid, Saeed, Haybron, Daniel M., Holton, Richard, Ignarro, Louis J., Jackson, Tamika, Jamieson, Dale, Jollimore, Jody, Karaba, Andrew, Klein, Marina, Lauer, Georg, Law, Mansun, Lemon, Stanley M., Liang, T. Jake, Liu, Lin, Lohmann, Volker, Mak, Lung-Yi, Marinho, Rui T., Marsh, Abigail A., Miller, Lesley, Morrison, Joshua, Negro, Francesco, Nguyen, Bao-Vuong, Page, Kimberly, Paterson, Kerry, Pedrana, Alisa, Pietschmann, Thomas, Pinker, Steven, Plotkin, Stanley, Ray, Stuart C., Reau, Nancy, Remak, William M., Rice, Charles M., Ridruejo, Ezequiel, Roberts, Richard J., Roth, Alvin, Rouphael, Nadine, Sanders, Rogier, Sandvold, Russell, Schafer, Arthur, Schinkel, Janke, Seto, Wai-Kay, Shoukry, Naglaa, Singer, Peter, Solomon, Sunil, Somerville, Chris, Sonderup, Mark W., Sulkowski, Mark, Talaat, Kawsar, Temkin, Larry, Terrault, Norah, Thio, Chloe, Thomas, David L., Thompson, Alexander J., Tzarum, Netanel, van der Valk, Marc, Van Gennip, Jennifer, Waked, Imam, Walen, Alec, Walker, Christopher M., Wedemeyer, Heiner, Weijer, Charles, Wikler, Dan, Wilkinson, Dominic, Youngs, Heather, Yuen, Man-fung, Zack, Barry, Zinger, Ekaterina, Alter, Harvey J, Biondi, Mia J, Cox, Andrea L, Eberts, Jake D, Feld, Jordan J, Liang, T Jake, Morrison, Josh, Rice, Charles M, Shoukry, Naglaa H, and Thomas, David L

Published
2023
Full Text
View/download PDF

41. Redefining the Paradigm: The Role of Sexual Networks and Sexualized Drug Use in the Transmission of Hepatitis C Virus Among Men Who Have Sex With Men.

Author

Fierer, Daniel S and Schinkel, Janke

Subjects
*HEPATITIS C, *HEPATITIS C virus, *DRUG utilization
Abstract

Keywords: condomless receptive anal intercourse (CRAI); HIV infection; methamphetamine; people who inject drugs (PWID); semen EN condomless receptive anal intercourse (CRAI) HIV infection methamphetamine people who inject drugs (PWID) semen 657 661 5 09/21/23 20230915 NES 230915 B (See the Major Article by Artenie et al on pages 662-73.) They conclude that injection drug use accounted for 43% of incident HCV infections, although injection use itself was reported by just 13% of MSM. Finally, regardless of route of infection, HCV transmission among MSM necessarily requires being part of one of the sparsely distributed sexual networks in which HCV is prevalent. A comparison of seminal hepatitis C virus (HCV) RNA levels during recent and chronic HCV infection in HIV-infected and HIV-uninfected individuals. [Extracted from the article]

Published
2023
Full Text
View/download PDF

42. Evaluating interventions to reduce behaviour associated with HCV reinfection in men who have sex with men: study protocol for a non-blinded, phase 2, randomised trial

Author

Hage, Kris, primary, Boyd, Anders, additional, Davidovich, Udi, additional, Zantkuijl, Paul, additional, Hoornenborg, Elske, additional, Matser, Amy, additional, Generaal, Ellen, additional, Schinkel, Janke, additional, Todesco, Eve, additional, Valk, Marc van der, additional, Hayette, Rougier, additional, Lacombe, Karine, additional, and Prins, Maria, additional

Published
2023
Full Text
View/download PDF

44. SARS-CoV-2 Vaccination Uptake in Six Ethnic Groups Living in Amsterdam, the Netherlands: A Registry-Based Study within the Helius Cohort

Author

Campman, Sophie, primary, Boyd, Anders, additional, Coyer, Liza, additional, Schinkel, Janke, additional, Agyemang, Charles, additional, Galenkamp, Henrike, additional, Koopman, Anitra D. M., additional, Chilunga, Felix P., additional, Schim van der Loeff, Maarten F., additional, van Houtum, Lieke, additional, Leenstra, Tjalling, additional, Stronks, Karien, additional, and Prins, Maria, additional

Published
2023
Full Text
View/download PDF

46. Hepatitis C virus transmission between eight high-income countries among men who have sex with men: a whole-genome analysis

Author

Koopsen, Jelle, Matthews, Gail, Rockstroh, Juergen, Applegate, Tanya L, Bhagani, Sanjay, Rauch, Andri, Grebely, Jason, Sacks-Davis, Rachel, Ingiliz, Patrick, Boesecke, Christoph, Rebers, Sjoerd, Feld, Jordan, Bruneau, Julie, Martinello, Marianne, Hellard, Margaret, Dore, Gregory J, Schinkel, Janke, and van der Valk, Marc

Subjects
610 Medicine & health
Abstract

BACKGROUND Microelimination of the hepatitis C virus (HCV) among men who have sex with men (MSM) could be complicated by continuous external introductions and the emergence of phylogenetic clusters harbouring clinically significant resistance-associated substitutions (RAS). To investigate international clustering and the prevalence and transmission of RAS, we aimed to analyse whole-genome HCV sequences from MSM with a recently acquired infection who participated in a large, international HCV treatment trial. METHODS For this whole-genome analysis, we obtained HCV sequences from 128 MSM who had acquired HCV within the past 12 months and were participating in the REACT trial. The participants from whom sequences were obtained were recruited at 24 sites in eight countries. We inferred maximum-likelihood phylogenies and identified transmission clusters for HCV genotypes separately. We constructed time-scaled phylogenies to estimate cluster introduction dates and used a Bayesian Skygrid approach to estimate the effective population size over the past 50 years. We calculated the prevalence of RAS and the extent of RAS transmission in the study population. FINDINGS The majority of recent HCV infections were part of international networks that arose in the late 1990s and early 2000s. Sequences obtained in the same country clustered frequently, and in 36% of subclusters since 2015 we found evidence of international transmission. European MSM were more likely than non-European MSM to be in a cluster (odds ratio 11·9 [95% CI 3·6-43·4], p

Published
2023
Full Text
View/download PDF

47. Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection—the InC³ Study

Author

Sacks-Davis, Rachel, Grebely, Jason, Dore, Gregory J., Osburn, William, Cox, Andrea L., Rice, Thomas M., Spelman, Timothy, Bruneau, Julie, Prins, Maria, Kim, Arthur Y., McGovern, Barbara H., Shoukry, Naglaa H., Schinkel, Janke, Allen, Todd M., Morris, Meghan, Hajarizadeh, Behzad, Maher, Lisa, Lloyd, Andrew R., Page, Kimberly, and Hellard, Margaret

Published
2015

48. Assay optimization for molecular detection of Zika virus/ Optimisation des tests pour la detection moleculaire du virus Zika/ Optimizacion de la prueba para la deteccion molecular del virus de Zika

Author

Corman, Victor M., Rasche, Andrea, Baronti, Cecile, Aldabbagh, Souhaib, Cadar, Daniel, Reusken, Chantal BEM, Pas, Suzan D., Goorhuis, Abraham, Schinkel, Janke, Molenkamp, Richard, Kiimmerer, Beate M., Bleicker, Tobias, Brunink, Sebastian, Eschbach-Bludau, Monika, Eis-Hubinger, Anna M., Koopmans, Marion P., Schmidt-Chanasit, Jonas, Grobusch, Martin P., de Lamballerie, Xavier, Drosten, Christian, and Drexler, Jan Felix

Subjects
Biological assay -- Innovations, Genotype -- Identification and classification, Molecular diagnostic techniques -- Innovations, Health
Abstract

Objective To examine the diagnostic performance of real-time reverse transcription (RT)-polymerase chain reaction (PCR) assays for Zika virus detection. Methods We compared seven published real-time RT-PCR assays and two new assays that we have developed. To determine the analytical sensitivity of each assay, we constructed a synthetic universal control ribonucleic acid (uncRNA) containing all of the assays' target regions on one RNA strand and spiked human blood or urine with known quantities of African or Asian Zika virus strains. Viral loads in 33 samples from Zika virus-infected patients were determined by using one of the new assays. Findings Oligonucleotides of the published real-time RT-PCR assays, showed up to 10 potential mismatches with the Asian lineage causing the current outbreak, compared with 0 to 4 mismatches for the new assays. The 95% lower detection limit of the seven most sensitive assays ranged from 2.1 to 12.1 uncRNA copies/reaction. Two assays had lower sensitivities of 17.0 and 1373.3 uncRNA copies/reaction and showed a similar sensitivity when using spiked samples. The mean viral loads in samples from Zika virus-infected patients were 5 x 104 RNA copies/mL of blood and 2 x [10.sup.4] RNA coples/mL of urine. Conclusion We provide reagents and updated protocols for Zika virus detection suitable for the current outbreak strains. Some published assays might be unsuitable for Zika virus detection, due to the limited sensitivity and potential incompatibility with some strains. Viral concentrations in the clinical samples were close to the technical detection limit, suggesting that the use of insensitive assays will cause false-negative results. Objectif Etudier la performance diagnostique des tests bases sur l'amplification en chaine par polymerase (PCR) en temps reel apres transcription inverse (RT) pour detecter le virus Zika. Methodes Nous avons compare sept tests publies utilisant la RT-PCR en temps reel et deux nouveaux tests developpes par nos soins. Afin de determiner la sensibilite analytique de chaque test, nous avons concu un acide ribonucleique synthetique de controle universel (ARNcun) contenant toutes les regions ciblees par les tests sur une helice ARN et enrichi de l'urine ou du sang humain de quantites connues de souches africaines ou asiatiques du virus Zika. Les charges virales dans 33 echantillons provenant de patients infectes par le virus Zika ont ete determinees a l'aide de l'un des nouveaux tests. Resultats Les oligonucleotides des tests publies utilisant la RT-PCR en temps reel ont presente jusqu'a TOmauvais apparlements potentiels avec la lignee asiatique provoquant l'epidemie actuelle, alors qu'on a constate de 0 a 4 mauvais appariements dans le cas des nouveaux tests. La limite de detection inferieure a 95% des sept tests les plus sensibles variait de 2,1 a 12,1 copies dARNcun/reaction. Deux tests presentaient des sensibilites plus basses de 17,0 et 1373,3 copies d'ARNcun/reaction et montraient une sensibilite similaire lorsque des echantillons enrichis etaient utilises. Les charges virales moyennes dans les echantillons provenant de patients infectes par le virus Zika etaient de 5 x 104 copies d'ARN/mL de sang et de 2 x 104 copies dARN/mL d'urine. Conclusion Nous proposons pour detecter le virus Zika des reactifs et des protocoles actualises, adaptes aux souches responsables de la flambee actuelle.Tous les tests publies ne permettent pas de detecter le virus Zika en raison d'une sensibilite limitee et d'une incompatibilite potentielle avec certaines souches. Les concentrations virales dans les echantillons cliniques etaient proches de la limite de detection technique, ce qui laisse penser que l'utilisation de tests insensibles donnera des resultats faussement negatifs. Objetivo Examinar el rendimiento del diagnostico de las pruebas de reaccion en cadena de la polimerasa de transcriptasa inversa (RT-PCR) en tiempo real para la deteccion del virus de Zika. Metodos Se compararon siete pruebas de RT-PCR en tiempo real publicadas y dos pruebas nuevas que se han desarrollado. Con el fin de determinar la sensibilidad analitica de cada prueba, se construyo un acido ribonucleico sintetico de control universal (uncRNA) que contenia todas las regiones objetivo de las pruebas en una hebra de RNA y se anadio a sangre u orina humana con cantidades conocidas de cepas de virus de Zika de Asia o Africa. Se determinaron las cargas viricas en 33 muestras procedentes de pacientes infectados por el virus de Zika a traves de una de las pruebas nuevas. Resultados Los oligonucleotidos de las pruebas de RT-PCR en tiempo real publicadas mostraron hasta 10 posibles discordancias con el linaje de Asia causante de los brotes actuales, en comparacion con 0 de 4 discordancias en el caso de las pruebas nuevas. El limite de deteccion inferior del 95% de las siete pruebas mas sensibles abarco de 2,1 a 12,1 copias/reaccion de uncRNA. Dos pruebas mostraron sensibilidades inferiores de 17,0 y 1373,3 copias/reaccion de uncRNA y presentaron una sensibilidad similar al usar muestras Infectadas. Las cargas viricas medias en las muestras procedentes de pacientes infectados por el virus de Zika fueron de 5 x 104 copias de RNA/mL de sangre y de 2 x [10.sup.4] coplas de RNA/ml de orina. Conclusion Se proporcionan reactivos y protocolos actualizados para la deteccion adecuada del virus de Zika en el caso de las cepas de brotes actuales. Algunas pruebas publicadas pueden no ser adecuadas para la deteccion del virus de Zika, debido a la limitada sensibilidad y a la posible incompatibilidad con algunas cepas. Las concentraciones viricas en las muestras clinicas se acercaron al limite de deteccion tecnico, lo que sugeria que el uso de pruebas Intensivas causaria resultados falsos negativos., Introduction The Zika virus is a mosquito-borne flavivirus with an approximately 11 kilobase ribonucleic acid (RNA) genome. (1) The virus usually causes a mild infection in adults, symptoms include fever, [...]

Published
2016
Full Text
View/download PDF

50. Low Risk of Failing Direct-Acting Antivirals in People With Human Immunodeficiency Virus/Hepatitis C Virus From Sub-Saharan Africa or Southeastern Asia: A European Cross-Sectional Study

Author

Isfordink, Cas, Boyd, Anders, Mocroft, Amanda, Kusejko, Katharina, Smit, Colette, de Wit, Stephane, Mahungu, Tabitha, Falconer, Karolin, Wandeler, Gilles, Cavassini, Matthias, Stöckle, Marcel, Schinkel, Janke, Rauch, Andri, Peters, Lars, van der Valk, Marc, University of Zurich, Infectious diseases, Medical Microbiology and Infection Prevention, AII - Infectious diseases, APH - Methodology, APH - Global Health, APH - Digital Health, and APH - Personalized Medicine

Subjects
hepatitis C virus, 10028 Institute of Medical Virology, 10234 Clinic for Infectious Diseases, Infectious Diseases, elimination, Oncology, human immunodeficiency virus, 610 Medicine & health, 610 Medizin und Gesundheit, coinfection
Abstract

Background Several studies have reported suboptimal efficacy of direct-acting antivirals (DAAs) to treat hepatitis C virus (HCV) subtypes endemic to sub-Saharan Africa (SSA) and Southeastern Asia (SEA). The extent of this issue in individuals with human immunodeficiency virus (HIV)/HCV from SSA or SEA residing in Europe is unknown. Methods We retrospectively analyzed data from several prospective European cohorts of people living with HIV. We included individuals with HIV/HCV who originated from SSA or SEA, were treated with interferon-free DAAs, and had an available HCV RNA result ≥12 weeks after the end of treatment. The primary outcome was sustained virological response at least 12 weeks after the end of treatment (SVR12). Results Of the 3293 individuals with HIV/HCV treated with DAA and with available SVR12 data, 142 were from SSA (n = 64) and SEA (n = 78). SVR12 was achieved by 60 (94% [95% confidence interval {CI}, 86%–98%]) individuals from SSA and 76 (97% [95% CI, 92%–99%]) from SEA. The genotypes of the 6 individuals failing DAA treatment were 2, 3a, 3h, 4a, 4c, and 6j. For 2 of the 4 unsuccessfully treated individuals with available sequence data at treatment failure, NS5A resistance-associated substitutions were present (30R/93S in an individual with genotype 4c and 31M in an individual with genotype 6j). Conclusions SVR12 rates were high in individuals with HIV/HCV residing in Europe and originating from regions where intrinsically NS5A-resistant HCV strains are endemic. HCV elimination for this population in Europe is unlikely to be hampered by suboptimal DAA efficacy.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results